Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PD-1 Antibody SHR-1210 Combined With Anti-angeogensis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy

Next Previous
X
Search
Trial Profile

Anti-PD-1 Antibody SHR-1210 Combined With Anti-angeogensis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PASSION
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 01 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2022 Planned End Date changed from 1 Mar 2020 to 1 Dec 2022.
    • 01 Jul 2022 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top